X4 PHARMACEUTICALS, INC Cash and Restricted Cash
X4 PHARMACEUTICALS, INC (XFOR) had Cash and Restricted Cash of $195.77 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $195.77M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $217.49M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $217.85M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.44M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $195.77M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $217.49M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $217.85M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $70.44M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $40.02M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $41.04M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $56.48M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $98.20M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $148.00M 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $61.27M 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $100.25M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $132.60M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $137.46M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $94.43M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $123.03M 10-K · filed 2026-03-17 | |
| 2022-09-30 | $81.15M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $48.68M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $67.74M 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $83.11M 10-K · filed 2025-03-26 | |
| 2021-09-30 | $77.72M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $96.49M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $116.66M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $80.70M 10-K · filed 2024-03-21 | |
| 2020-09-30 | $90.72M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $105.64M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $116.95M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $128.09M 10-K · filed 2023-03-21 | |
| 2019-09-30 | $77.01M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $95.64M 10-Q · filed 2020-08-04 | |
| 2019-03-31 | $23.25M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $8.50M 10-K · filed 2022-03-17 | $31.39M 10-K · filed 2019-03-11 |
| 2018-09-30 | $10.20M 10-Q · filed 2019-11-07 | $41.35M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $12.93M 10-Q · filed 2019-08-07 | $50.29M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $19.21M 10-Q · filed 2019-05-15 | $64.36M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $27.05M 10-K · filed 2021-03-19 | $77.15M 10-Q · filed 2018-05-10 |
| 2017-09-30 | $31.72M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $32.84M 10-Q · filed 2018-08-13 | |
| 2017-03-31 | $4.25M 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $15.31M 10-K · filed 2020-03-12 | $3.43M 10-Q · filed 2018-05-10 |
| 2015-12-31 | $7.10M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |